FDA approval of ASCENIV for patients aged two years and older expands the product’s primary humoral immunodeficiency indication, allowing earlier treatment for younger patients.
The approval follows completion of a required post‑marketing pediatric assessment, and it opens a new patient segment that was previously limited to those 12 and older. The pediatric market is estimated to include roughly 10,000–12,000 patients in the U.S., potentially adding $200–$300 million in annual revenue at current pricing.
ADMA’s financials show ASCENIV generated $362.5 million in 2025, up 51% YoY, and the company expects FY 2026 revenue to exceed $635 million, driven in part by the expanded label. Gross margin for 2025 was 57.4%, up from 51.5% in 2024, reflecting a mix shift toward higher‑margin IVIG products and yield‑enhanced production.
Management highlighted the strategic importance of the expansion. President and CEO Adam Grossman said the new label “allows ADMA to actively address the treatment needs of younger PI and immune‑compromised patients earlier in their treatment journey.” COO Kaitlin Kestenberg noted the successful completion of the pediatric trials as a testament to the company’s clinical and operational execution.
The approval strengthens ADMA’s position as a leading U.S. plasma‑derived biologics manufacturer, complementing its existing portfolio of BIVIGAM and NABI‑HB. The expanded label also positions the company to capture market share from competitors such as CSL Behring and Octapharma, who offer pediatric IVIG products but lack the same FDA‑approved indication.
With the expanded label, ADMA anticipates accelerated growth in the pediatric segment, potentially increasing ASCENIV’s market share and reinforcing its high‑margin business model. The company’s recent yield‑enhancement approval in April 2025 further supports production scalability and margin improvement.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.